Cedars‑Sinai scientists published a paper in Science Translational Medicine describing TY1, a synthetic RNA‑based molecule modeled on exosomal sequences that augments TREX1 activity in macrophages to clear damaged DNA and promote cardiac repair. Preclinical studies demonstrated reduced scarring and improved function after ischemic injury in animal models. Investigators positioned TY1 as the prototype of a new 'exomer' drug class that harnesses RNA envelopes for tissue repair without stem cells. The team described sequencing exosome cargo to identify therapeutic RNAs and engineered TY1 to mimic clinically validated RNA drug structures. The work was led by Eduardo Marbán and collaborators at the Smidt Heart Institute.